US Bancorp
MRNA icon

US Bancorp’s Moderna MRNA Stock Holding History

US Bancorp’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
14,487
+1,007
+7% +$52.1K ﹤0.01% 1191
2026
Q1 		$685K Buy
13,480
+2,374
+21% +$111K ﹤0.01% 1339
2025
Q4 		$328K Sell
11,106
-2,271
-17% -$61.7K ﹤0.01% 1766
2025
Q3 		$346K Sell
13,377
-5,718
-30% -$160K ﹤0.01% 1719
2025
Q2 		$527K Buy
19,095
+8,436
+79% +$222K ﹤0.01% 1473
2025
Q1 		$302K Sell
10,659
-6,303
-37% -$224K ﹤0.01% 1783
2024
Q4 		$705K Buy
16,962
+2,280
+16% +$109K ﹤0.01% 1297
2024
Q3 		$1M Sell
14,682
-7,512
-34% -$690K ﹤0.01% 1132
2024
Q2 		$2.64M Sell
22,194
-913
-4% -$116K ﹤0.01% 749
2024
Q1 		$2.46M Buy
23,107
+3,771
+20% +$380K ﹤0.01% 766
2023
Q4 		$1.92M Sell
19,336
-1,046
-5% -$88K ﹤0.01% 843
2023
Q3 		$2.11M Sell
20,382
-720
-3% -$80.3K ﹤0.01% 782
2023
Q2 		$2.56M Sell
21,102
-2,377
-10% -$317K ﹤0.01% 719
2023
Q1 		$3.61M Sell
23,479
-1,173
-5% -$194K 0.01% 630
2022
Q4 		$4.43M Buy
24,652
+3,305
+15% +$540K 0.01% 567
2022
Q3 		$2.52M Buy
21,347
+667
+3% +$101K 0.01% 688
2022
Q2 		$2.96M Buy
20,680
+5,705
+38% +$815K 0.01% 673
2022
Q1 		$2.58M Buy
14,975
+1,724
+13% +$290K ﹤0.01% 791
2021
Q4 		$3.37M Buy
13,251
+328
+3% +$95.9K 0.01% 714
2021
Q3 		$4.97M Sell
12,923
-4,819
-27% -$1.78M 0.01% 560
2021
Q2 		$4.17M Sell
17,742
-9,405
-35% -$1.68M 0.01% 619
2021
Q1 		$3.56M Sell
27,147
-12,634
-32% -$1.83M 0.01% 642
2020
Q4 		$4.16M Buy
39,781
+34,560
+662% +$3.5M 0.01% 576
2020
Q3 		$369K Buy
5,221
+766
+17% +$53.4K ﹤0.01% 1494
2020
Q2 		$286K Buy
4,455
+2,152
+93% +$118K ﹤0.01% 1583
2020
Q1 		$69K Buy
2,303
+2,120
+1,158% +$48.8K ﹤0.01% 2198
2019
Q4 		$4K Buy
+183
New +$3.25K ﹤0.01% 3339

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

US Bancorp's MRNA Position: Q2 2026 in Review

US Bancorp increased its Moderna (MRNA) stake by 7.5% in Q2 2026, buying an estimated $52.1K and bringing the position to 14,487 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1191.

US Bancorp first reported a position in MRNA in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.97M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • US Bancorp held 14,487 shares of Moderna worth $1.01M as of Q2 2026.
  • US Bancorp bought 1,007 Moderna shares in Q2 2026, an estimated $52.1K.
  • Moderna made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1191 holding.
  • US Bancorp first reported a position in Moderna in Q4 2019 and has held it in 27 quarters since.
  • US Bancorp's Moderna position peaked at $4.97M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.